Navigation Links
Biomoda and Medical Acoustics Partner in Study for Early Detection of Lung Cancer in Veterans
Date:2/13/2008

Innovative Lung Flute(R) to be used to provide cost-efficient, easy to use

method of collecting lung sputum samples for testing

ALBUQUERQUE, N.M., Feb. 13 /PRNewswire-FirstCall/ -- Biomoda, Inc. (OTC Bulletin Board: BMOD), a maker of patented early lung cancer detection testing and other cancer diagnostic technology, today announced a collaborative agreement with Medical Acoustics, LLC, to collect lung sputum samples in an upcoming clinical study that will use Biomoda's proprietary testing technology for detection of early lung cancer.

Biomoda's non-invasive and cost-efficient screening technology identifies cancerous or aberrant cells extracted from samples of lung sputum; cancerous cells glow red under fluorescent light and can be detected under a microscope. Current diagnostic methods for lung cancer often detect the disease only at more advanced stages.

Medical Acoustics' Lung Flute(R) is a minimally invasive, flute-shaped device that uses low frequency sound waves to help patients with the natural mucus clearing system. When a patient exhales through the mouthpiece of the device, the exhalation generates specific sound waves that vibrate cilia and the airways, causing deep lung secretions to thin and be expelled by coughing. The FDA-cleared technology produces sputum samples without the need for saline induction.

The Lung Flute(R) will be used during an upcoming clinical program that will be administered by New Mexico Institute of Mining and Technology (New Mexico Tech) in partnership with the New Mexico Department of Veterans Services (DVS). Biomoda will conduct the first year of the $350,000 clinical program, while New Mexico Tech and DVS will oversee the program and provide treatment to those veterans who test positive for lung cancer.

"The Lung Flute(R) presents a safe, effective, convenient and rapid method of sputum induction for patients participating in our veterans' clinical study for lung cancer," said Connie Dorian, Director of Technical Operations for Biomoda. "Sputum induction with the Lung Flute is safer, less time consuming, more convenient and better tolerated by patients than induction with hypertonic saline."

"The opportunity to partner with Biomoda on this innovative study of lung cancer in veterans opens the door to more broadly demonstrate the benefits that our easy to use and minimally invasive technology can provide to patients everywhere. The study also provides further evidence of the vast number of potential applications for the Lung Flute(R)," said Terry Cryan, President and CEO of Medical Acoustics.

Dr. Nicolaas J. Smit, Medical Acoustics' Vice President of Science and Technology, added, "As the unique properties of the Lung Flute(R) become apparent to practitioners, we believe the opportunities for early detection of lung cancer will increase significantly. Our participation in this study offers an important opportunity to learn more about the treatment of all diseases of the pulmonary system."

About Biomoda

Biomoda, Inc. is a developmental stage company engaged in developing biopharmaceutical technology to diagnose and treat human diseases. The Company currently licenses two patents in the U.S. and has a third patent pending. In addition, the Company has patents in Australia, Brazil, Canada, Japan, Korea and Russia, and through the European Patent Office, in Belgium, Switzerland, Germany, Denmark, Spain, France, Great Britain, Italy and the Netherlands.

Biomoda's business opportunities are in developing products for the early detection and targeted treatment of cancers. The initial products relate to lung cancer and are based on commercializing the Company's core patent protected technology. More information on the Company can be found at http://www.biomoda.com.

About Medical Acoustics

Medical Acoustics' mission is to design and develop devices employing acoustic technologies for diagnostic and therapeutic medical applications. It is a privately held, commercial-stage medical device company located in Buffalo, New York that has been built on ten years of research and development in the science of applied acoustics.

The Company's first product, the patented and FDA-cleared Lung Flute(R), is a revolutionary medical device which is expected to play a significant role in drug development for asthma, chronic bronchitis, community-acquired pneumonia, lung cancer and tuberculosis. More information on the Company and the Lung Flute(R) can be found at http://www.medicalacoustics.com.

Safe Harbor Statement

This release may contain forward-looking statements made pursuant to the Private Securities Litigation Reform Act of 1995. Such statements, including statements regarding clinical trials, patents, and forecasts of future results involve significant risks and uncertainties and actual results could differ materially from those expressed or implied herein. Factors that could cause such differences include, but are not limited to, risks associated with new product development, competitive risks to marketed products and availability of required financing and other sources of funds on acceptable terms, if at all, as well as the risks discussed in the Company's filings with the Securities and Exchange Commission. The Company is not under any obligation, and the Company expressly disclaims any obligation, to update or alter any forward-looking statements, whether as a result of new information, future events or otherwise.

Contact: Jamila Taylor

Calypso Communications

603-431-0816

jtaylor@calypsocom.com


'/>"/>
SOURCE Biomoda, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. WallSt.net Announces Upcoming Interview With CEO of Biomoda
2. Biomoda Hires Manzano Strategies LLC to Spearhead Government Affairs Efforts
3. Biomoda, Inc. Retains MicroCap Management, LLC as its Lead Corporate Communications and Broker Relations Firm.
4. Biomoda Announces Collaborative Agreement With New Mexico Tech
5. Biomoda Hires Senior Scientist to Expand Research & Development Effort
6. AEterna Zentaris completes management team with the appointment of Chief Medical Officer
7. VisEn Medical Files Action to Invalidate New Caliper Life Sciences Patent
8. China Medical Technologies to Participate in the Morgan Stanleys 2007 China Medical Corporate Day
9. Pathway Medical Technologies Adds Joe Rafferty as VP, Sales, and Moves To Larger Facility to Accommodate Rapid Growth
10. BioMS Medical announces its intention to renew a normal course issuer bid
11. Dr. Amit Dhawan Promoted to Medical Director for The Mattson Jack Group
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... ... Sciences today announced the three Winners and six Finalists of the 2017 Blavatnik ... annually by the Blavatnik Family Foundation and administered by the New York Academy ...
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... ... Surgical Wound Market with the addition of its newest module, US Hemostats & ... market for thrombin hemostats, absorbable hemostats, fibrin sealants, synthetic sealants and biologic sealants ...
(Date:10/11/2017)... ... October 11, 2017 , ... ... President Andi Purple announced Dr. Suneel I. Sheikh, the co-founder, CEO and chief ... ), Inc. has been selected for membership in ARCS Alumni Hall of ...
(Date:10/11/2017)... ... 11, 2017 , ... ComplianceOnline’s Medical Device Summit is back for its 4th ... in San Francisco, CA. The Summit brings together current and former FDA office bearers, ... and government officials from around the world to address key issues in device compliance, ...
Breaking Biology Technology:
(Date:4/6/2017)... , April 6, 2017 Forecasts ... ANPR, Document Readers, by End-Use (Transportation & Logistics, Government ... Oil, Gas & Fossil Generation Facility, Nuclear Power), Industrial, ... Other) Are you looking for a definitive ... ...
(Date:4/3/2017)... 2017  Data captured by IsoCode, IsoPlexis ... a statistically significant association between the potency ... and objective response of cancer patients post-treatment. ... whether cancer patients will respond to CAR-T ... as to improve both pre-infusion potency testing and ...
(Date:3/28/2017)... March 28, 2017 The report ... (Camera, Monitors, Servers, Storage Devices), Software (Video Analytics, VMS), ... - Global Forecast to 2022", published by MarketsandMarkets, the ... and is projected to reach USD 75.64 Billion by ... 2022. The base year considered for the study is ...
Breaking Biology News(10 mins):